Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003331 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00003331 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 30 participants.
The verdict
NCT00003331, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining topotecan, fluorouracil, and leucovorin in treating patients who have advanced cancer.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1998-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003331
The ClinicalTrials.gov registry entry for NCT00003331 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00003331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003331 about?
NCT00003331 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining topotecan, fluorouracil, and leucovorin in treating patients...
What is the current status of trial NCT00003331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1998-01.
What interventions are being tested in trial NCT00003331?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003331?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.